Trending...
- Team Crush Yard Wins Gold Medal at 2024 Joola Pickleball With Orlando Director of Pickleball
- PalletOne Unveils a Four-Part Blog Series on Optimizing Pallet Specifications for Bids
- Greater Fort Myers Chamber CEO Robert Goltz receives service award
NRXP: Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics.
MIAMI - Floridant -- NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
On August 26th NRXP announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
More on The Floridant
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange. Additional information to be presented by NRXP at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024.
NRXP has formed partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality.
In March 2024 NRXP demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.
NRXP presented final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression4 at the American Society of Clinical Psychopharmacology's annual meeting. These data demonstrated a significantly improved safety profile versus the standard of care, as demonstrated by a clinically significant reduction in akathisia (P=0.025) and time to sustained remission from suicidality (P=0.05). Akathisia is an adverse event seen with antidepressant medications considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA for Accelerated Approval to the US FDA for treatment of bipolar depression patients with suicidality or akathisia, based on these data as well as additional data from our STABIL-B5 trial.
HOPE Therapeutics, is an NXRP subsidiary that will focus on the delivery of advance psychiatric treatments, including ketamine-focused treatment for depression and suicidality. Unlike the core business of NRXP, that is focused on biotechnology Research and Development, HOPE is organized around consolidating existing best-in-class clinics into a nationwide network. This has been done previously and without much success with clinics that are not necessarily psychiatrist-led. With Hope ownership as an asset of NRXP, this will further strengthen the NRXP balance sheet and aims to further enhance shareholder value.
More on The Floridant
NRX-101 for Treatment of Chronic Pain:
In 2023, NRXP licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD.
During Q3 2023, NRXP tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRXP was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.
Should NRX-101 succeed in clinical trials, NRXP will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
NRXP recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.
Additionally, should NRXP or its partners succeed in serving 10% of the cUTI market, NRXP believes that the revenue from NRX-101 has the potential to be hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com/
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
On August 26th NRXP announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
More on The Floridant
- Eminent Jurist Endorses New Method to End the Grind of Legal Calendaring
- Composer Andrew Prahlow to Perform Award-Winning Outer Wilds Soundtrack on Oct 17th at Brooklyn's Music Hall of Williamsburg
- AXELERA Technologies Prepares for AUSA Annual meeting, Showcasing the 3d_4X Joystick
- The New Real Estate "Just Looking" Program Is A Big Hit With Central Florida Residents!
- The Florida Forum Speaker Series to Welcome Rt Hon Boris Johnson
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange. Additional information to be presented by NRXP at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024.
NRXP has formed partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality.
In March 2024 NRXP demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.
NRXP presented final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression4 at the American Society of Clinical Psychopharmacology's annual meeting. These data demonstrated a significantly improved safety profile versus the standard of care, as demonstrated by a clinically significant reduction in akathisia (P=0.025) and time to sustained remission from suicidality (P=0.05). Akathisia is an adverse event seen with antidepressant medications considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA for Accelerated Approval to the US FDA for treatment of bipolar depression patients with suicidality or akathisia, based on these data as well as additional data from our STABIL-B5 trial.
HOPE Therapeutics, is an NXRP subsidiary that will focus on the delivery of advance psychiatric treatments, including ketamine-focused treatment for depression and suicidality. Unlike the core business of NRXP, that is focused on biotechnology Research and Development, HOPE is organized around consolidating existing best-in-class clinics into a nationwide network. This has been done previously and without much success with clinics that are not necessarily psychiatrist-led. With Hope ownership as an asset of NRXP, this will further strengthen the NRXP balance sheet and aims to further enhance shareholder value.
More on The Floridant
- Mobile windshield service provides welcome post-storm relief
- Cell-Ed and National Minority Health Association Forge Strategic Partnership to Expand Caregiving and Health Equity Initiatives
- Fortius Metals secures $2 Million Additional Funding to Bring Advanced Metal 3D Printing to the Aerospace and Defense Industry
- Voices Rising Festival Celebrates Diversity in E. Islip, GRAMMY Governor LACHI performs!
- DiSTI's GL Studio SC Powers New Guardian UAV Ground Control System
NRX-101 for Treatment of Chronic Pain:
In 2023, NRXP licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD.
During Q3 2023, NRXP tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRXP was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.
Should NRX-101 succeed in clinical trials, NRXP will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
NRXP recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.
Additionally, should NRXP or its partners succeed in serving 10% of the cUTI market, NRXP believes that the revenue from NRX-101 has the potential to be hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com/
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on The Floridant
- CCHR Demands Justice for Victims of Psychiatric Fraud and Patient Sexual Abuse
- First World Chronic Cough Day October 15, 2024
- New Frontier Aerospace Closes Seed Round with Pacific Bays Capital
- National Good Vibes Day Summit to Feature Global Coherence Meditation with Heart-Math Institute App
- Florida: Governor Ron DeSantis Issues Updates on State Preparedness Efforts for Tropical Storm Milton
- 123waterfilters.com Domain Now For Sale
- Tradeshow Essentials "Enhance the Effectiveness of your Tradeshow Marketing"
- Florida: MEMORANDUM: EXECUTIVE ORDER NUMBER 24-215 (Emergency Management -Amending Executive Order 24-214 – Tropical Storm Milton)
- MMCG Invest and Innowave Studio Merge to Revolutionize Feasibility Studies and Site Plans
- Tint Academy USA Announces Window Tint Certification Course in Orlando, Florida
- Florida: EMORANDUM: EXECUTIVE ORDER NUMBER 24-214 (Emergency Management – Tropical Storm Milton)
- State of Nayarit Named the Official Mexican Tourism Destination of the Vancouver Canucks
- Sequentex Names Xcitium as Featured Supplier for Cybersecurity Awareness Month
- Mounts Botanical Garden to Present RIBBIT THE EXHIBIT II with 18 Larger-Than-Life Frog Sculptures
- LG Lesmo's Extendable High Table: Where Flexibility Meets Italian Craftsmanship
- The Magic Table by LG Lesmo: The Ultimate Space-Saving Solution
- Nails, Wax Eyebrow Threading, Hair Extensions, Spray Tans, Hair Stylists, and Hair Color Experts!
- Braswell Group Announces Speaker Lineup for 2024 Live 2 Lead Leadership Conference in Orland
- Ismael Cala Foundation and FICOP join forces to enhance the emotional education of young Hispanics USA - English USA - español
- Benchmark International Faciltd BT International Restaurant Distributors & Hart & Price Corporation